Boxer Capital’s Sage Therapeutics SAGE Stock Holding History

Boxer Capital’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,094,000	Closed	-$22.5M	–	67
2023 Q3	$22.5M	Hold	1,094,000	–	–	1.2%	29
2023 Q2	$51.4M	Hold	1,094,000	–	–	2.39%	14
2023 Q1	$45.9M	Hold	1,094,000	–	–	2.26%	12
2022 Q4	$41.7M	Hold	1,094,000	–	–	2.2%	14
2022 Q3	$42.8M	Hold	1,094,000	–	–	2.41%	11
2022 Q2	$35.3M	Hold	1,094,000	–	–	2.24%	18
2022 Q1	$36.2M	Hold	1,094,000	–	–	1.86%	17
2021 Q4	$46.5M	Hold	1,094,000	–	–	1.81%	17
2021 Q3	$48.5M	Hold	1,094,000	–	–	1.69%	14
2021 Q2	$62.1M	Hold	1,094,000	–	–	2.19%	9
2021 Q1	$81.9M	Hold	1,094,000	–	–	2.78%	6
2020 Q4	$94.6M	Hold	1,094,000	–	–	3.04%	8
2020 Q3	$66.9M	Hold	1,094,000	–	–	2.31%	10
2020 Q2	$45.5M	Sell	1,094,000 -438,510	-29%	-$15.9M	2%	14
2020 Q1	$44M	Buy	1,532,510 +1,182,510	+338%	+$68.5M	3%	10
2019 Q4	$25.3M	Buy	+350,000	New	+$43.1M	1.43%	19

Other funds holding SAGE

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's SAGE Position: Q4 2023 in Review

Boxer Capital sold out of Sage Therapeutics (SAGE) in Q4 2023, closing a stake of 1,094,000 shares — an estimated $22.5M sold.

Boxer Capital first reported a position in SAGE in Q4 2019 and held it in 16 quarters. The position peaked at $94.6M in Q4 2020. 201 funds tracked by Wall St. Rank hold SAGE as of Q4 2023.

Boxer Capital reported no remaining Sage Therapeutics position as of Q4 2023 after selling out during the quarter.
Boxer Capital sold 1,094,000 Sage Therapeutics shares in Q4 2023, an estimated $22.5M.
Boxer Capital first reported a position in Sage Therapeutics in Q4 2019 and held it in 16 quarters.
Boxer Capital's Sage Therapeutics position peaked at $94.6M in Q4 2020.
201 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2023.

Based on Boxer Capital's 13F filing for Q4 2023, filed 14 Feb 2024.